The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.

Through all the market madness of the past two years, there has been one truth universally acknowledged by the analysts who ...

Eli Lilly's (LLY) cease-and-desist letter is dismissed by weight loss drug compounder, OrderlyMeds. Read more here.

Eli Lilly (LLY) stock in focus as the company projects earnings headwinds from IPR&D charges estimated at $1.57B for Q1 2025.